Steven D. Rubin - 30 Jan 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Steven D. Rubin
Issuer symbol
N/A
Transactions as of
30 Jan 2023
Net transactions value
$0
Form type
4
Filing time
31 Jan 2023, 15:09:58 UTC
Previous filing
13 Oct 2022
Next filing
19 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +2,859 $0.000000 2,859 30 Jan 2023 Common Stock 2,859 $4.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.